Notice of Annual General Meeting
Released
Released
Announcement PDF
Notice of Annual General Meeting 2024
Radiopharm Theranostics Limited ACN 647 877 889
Notice of Annual General Meeting
Radiopharm Theranostics Limited ACN 647 877 889
Notice is given that the Annual General Meeting of Radiopharm Theranostics Limited ACN 647 877 889
(Company) will be held at:
Location
Level 3, 62 Lygon Street, Carlton, Victoria 3053 and virtually (online) at
https://bit.ly/RAD-AGM-2024
Date
Monday, 25 November 2024
Time
10:00 am (Melbourne time)
Registration from 9:45 am (Melbourne time)
Online meeting details
The 2024 Annual General Meeting (AGM or Meeting) will be webcast live via an online platform. To
participate you will need a desktop or mobile/tablet device with internet access. When you log onto the
online platform to register to attend the Meeting, you will need to provide your details (including SRN or
HIN) to be verified as a Shareholder.
All Shareholders have the opportunity to attend and participate in the Meeting online via internet
connection (using a computer, laptop, tablet or smartphone).
To register for the meeting, please click the link below:
https://bit.ly/RAD-AGM-2024
After registering, you will receive a confirmation email containing information about joining the Meeting.
For further details and instructions, please see the online meeting guide located on the Company website
containing details on attending and voting at the Meeting.
If Shareholders are unable to attend the Meeting using the online platform they are encouraged to
alternatively, return the proxy form to the Company in accordance with the instructions thereon.
Returning the proxy form will not preclude a Shareholder from attending and voting at the Meeting
utilising the online platform should they elect to do so.
If you have any questions regarding attendance at, or submitting questions for, the Meeting, please
contact the Company’s share registry, Automic Group, by telephone on 1300 288 664 (from within
Australia) or +61 2 9698 5414 (outside of Australia).
Shareholder Questions
In accordance with the Corporations Act, reasonable opportunity will be given to Shareholders at the
Meeting to ask questions about, or make comments on, the Meeting, the Company’s management and
the Remuneration Report, or the Company itself.
Notice of Annual General Meeting
1
A reasonable opportunity will also be given to Shareholders of the Meeting to ask the Company’s auditor,
Grant Thornton Australia (Auditor), questions relevant to the auditor’s report or conduct of the audit,
the preparation and contents of the audit report, the content of the audit, the independence of the
Auditor in relation to the conduct of the audit and the accounting policies adopted by the Company in
preparation of the financial statements. The Auditor will be given a reasonable opportunity to answer
written questions submitted by Shareholders of the Meeting.
In accordance with section 250PA of the Corporations Act, written questions for the Auditor must be
submitted to the Company by no later than the fifth business day before the day on which the Meeting is
to be held. In this case, no later than 18 November 2024.
Notice of Annual General Meeting
2
Ordinary Business
Financial Statements and Reports
To consider and receive the financial report, the Directors’ report and the auditor’s report for the year
ended 30 June 2024.
Resolution 1 – Remuneration Report
To consider and, if in favour, pass the following resolution in accordance with section 250R(2)
Corporations Act:
1
‘That the Remuneration Report be adopted.’
Note: This resolution shall be determined under section 250R(2) Corporations Act. Votes must not be cast on this
resolution by Key Management Personnel and closely related parties in contravention of section 250R or 250BD
Corporations Act. Restrictions also apply to votes cast as proxy unless exceptions apply.
The Directors abstain, in the interests of corporate governance, from making a recommendation in
relation to this resolution.
Under the Corporations Act, the vote on the Remuneration Report is advisory only and does not bind the
Directors or the Company.
Resolution 2 – Re-election of Director – Mr Ian Turner
To consider and, if in favour, pass the following resolution as an ordinary resolution:
2
‘That, Mr Ian Turner, a Director, who retires by rotation in accordance with Listing Rule 14.4 and
rule 19.3 of the Company’s constitution (Constitution), and being eligible, be re-elected as a
Director of the Company.’
Note: Further information about the candidate appears in the Explanatory Memorandum.
The Directors (with Mr Turner abstaining) unanimously recommend that you vote in favour of this
resolution.
Resolution 3 – Election of Director – Mr Phillip Hains
To consider and, if in favour, pass the following resolution as an ordinary resolution:
3
‘That, Mr Phillip Hains, who, having previously been appointed to fill a casual vacancy, retires in
accordance with Listing Rule 14.4 and rule 19.3 of the Company’s Constitution and having
consented to act and being eligible, be elected as Director of the Company.’
Note: Further information about the candidate appears in the Explanatory Memorandum.
The Directors (with Mr Hains abstaining) unanimously recommend that you vote in favour of this
resolution.
Resolution 4 – Election of Director – Mr Noel Donnelly
To consider and, if in favour, pass the following resolution as an ordinary resolution:
Notice of Annual General Meeting
3
4
‘That, Mr Noel Donnelly, who, having previously been appointed to fill a casual vacancy, retires in
accordance with Listing Rule 14.4 and rule 19.3 of the Company’s Constitution and having
consented to act and being eligible, be elected as Director of the Company.’
Note: Further information about the candidate appears in the Explanatory Memorandum.
The Directors (with Mr Donnelly abstaining) unanimously recommend that you vote in favour of this
resolution
Special business
Resolution 5 – Ratification of prior issue of Tranche 1 Shares
To consider and, if in favour, to pass the following resolution as an ordinary resolution:
5
‘That, for the purpose of Listing Rule 7.4 and for all other purposes, Shareholders ratify the issue
of 97,130,727 Tranche 1 Shares to Sophisticated Investors, on the terms set out in the
Explanatory Memorandum.’
The Directors unanimously recommend that you vote in favour of this resolution.
Resolution 6 – Approval to issue Remuneration Options to Director – Mr Paul
Hopper
To consider and, if in favour, to pass the following as an ordinary resolution:
6
‘That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the
granting of 8,000,000 unlisted options to Mr Paul Hopper, or his nominee, under the Company’s
Omnibus Incentive Plan, on the terms set out in the Explanatory Memorandum.’
Note: if approval is obtained under Listing Rule 10.14, approval is not required under Listing Rule 7.1 or Listing Rule
10.11, as set out in the Explanatory Memorandum.
The Directors abstain, in the interests of corporate governance from making a recommendation in
relation to this resolution.
Resolution 7 – Approval to issue Incentive Options to Director – Mr Riccardo
Canevari
To consider and, if in favour, to pass the following as an ordinary resolution:
7
‘That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the
granting of 55,250,286 unlisted options to Mr Riccardo Canevari, or his nominee, under the
Company’s Omnibus Incentive Plan, on the terms set out in the Explanatory Memorandum.’
Note: if approval is obtained under Listing Rule 10.14, approval is not required under Listing Rule 7.1 or Listing Rule
10.11, as set out in the Explanatory Memorandum.
The Directors abstain, in the interests of corporate governance from making a recommendation in
relation to this resolution.
Notice of Annual General Meeting
4
Resolution 8 – Approval to issue Incentive Options to Director – Mr Ian
Turner
To consider and, if in favour, to pass the following as an ordinary resolution:
8
‘That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the
granting of 4,040,404 unlisted options to Mr Ian Turner, or his nominee, under the Company’s
Omnibus Incentive Plan, on the terms set out in the Explanatory Memorandum.’
Note: if approval is obtained under Listing Rule 10.14, approval is not required under Listing Rule 7.1 or Listing Rule
10.11, as set out in the Explanatory Memorandum.
The Directors abstain, in the interests of corporate governance from making a recommendation in
relation to this resolution.
Resolution 9 – Approval to issue Remuneration Options to Director – Mr Ian
Turner
To consider and, if in favour, to pass the following as an ordinary resolution:
9
‘That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the
granting of 8,000,000 unlisted options to Mr Ian Turner, or his nominee, under the Company’s
Omnibus Incentive Plan, on the terms set out in the Explanatory Memorandum.’
Note: if approval is obtained under Listing Rule 10.14, approval is not required under Listing Rule 7.1 or Listing Rule
10.11, as set out in the Explanatory Memorandum.
The Directors abstain, in the interests of corporate governance from making a recommendation in
relation to this resolution.
Resolution 10 – Approval to issue Remuneration Options to Director –
Mr Noel Donnelly
To consider and, if in favour, to pass the following as an ordinary resolution:
10
‘That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the
granting of 8,000,000 unlisted options to Mr Noel Donnelly, or his nominee, under the Company’s
Omnibus Incentive Plan, on the terms set out in the Explanatory Memorandum.’
Note: if approval is obtained under Listing Rule 10.14, approval is not required under Listing Rule 7.1 or Listing Rule
10.11, as set out in the Explanatory Memorandum.
The Directors abstain, in the interests of corporate governance from making a recommendation in
relation to this resolution.
Resolution 11 – Approval to issue Remuneration Options to Director –
Mr Phillip Hains
To consider and, if in favour, to pass the following as an ordinary resolution:
11
‘That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the
granting of 8,000,000 unlisted options to Mr Phillip Hains, or his nominee, under the Company’s
Omnibus Incentive Plan, on the terms set out in the Explanatory Memorandum.’
Notice of Annual General Meeting
5
Note: if approval is obtained under Listing Rule 10.14, approval is not required under Listing Rule 7.1 or Listing Rule
10.11, as set out in the Explanatory Memorandum.
The Directors abstain, in the interests of corporate governance from making a recommendation in
relation to this resolution.
Resolution 12 – Approval to issue Remuneration Options to Director –
Ms Hester Larkin
To consider and, if in favour, to pass the following as an ordinary resolution:
12
‘That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the
granting of 8,000,000 unlisted options to Ms Hester Larkin, or her nominee, under the Company’s
Omnibus Incentive Plan, on the terms set out in the Explanatory Memorandum.’
Note: if approval is obtained under Listing Rule 10.14, approval is not required under Listing Rule 7.1 or Listing Rule
10.11, as set out in the Explanatory Memorandum.
The Directors abstain, in the interests of corporate governance from making a recommendation in
relation to this resolution.
Resolution 13 – Approval to issue Remuneration Options to Director –Dr Leila
Alland
To consider and, if in favour, to pass the following as an ordinary resolution:
13
‘That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the
granting of 8,000,000 unlisted options to Dr Leila Alland, or her nominee, under the Company’s
Omnibus Incentive Plan, on the terms set out in the Explanatory Memorandum.’
Note: if approval is obtained under Listing Rule 10.14, approval is not required under Listing Rule 7.1 or Listing Rule
10.11, as set out in the Explanatory Memorandum.
The Directors abstain, in the interests of corporate governance from making a recommendation in
relation to this resolution.
Resolution 14 – Approval of 10% capacity under Listing Rule 7.1A
To consider and, if in favour, to pass the following as a special resolution:
14
‘That, for the purposes of Listing Rule 7.1A and for all other purposes, Shareholders approve the
Company having the additional capacity to issue equity securities up to 10% of the issued capital
of the Company (at the time of issue) calculated in accordance with the formula prescribed in
Listing Rule 7.1A.2 over a 12 month period from the date of the Annual General Meeting, at a
price no less than that determined pursuant to Listing Rule 7.1A.3 and otherwise on the terms
and conditions set out in the Explanatory Memorandum.’
The Directors unanimously recommend that you vote in favour of this resolution.
Resolution 15 – Approval to issue Equity Securities under the Omnibus
Incentive Plan
To consider and, if in favour, to pass the following as an ordinary resolution:
Notice of Annual General Meeting
6
15
‘That for the purpose of Listing Rule 7.2, Exception 13 and sections 200B and 200E of the
Corporations Act and for all other purposes, the Company hereby approves the renewal of the
Company’s Employee Share Option Plan, the terms and conditions of which are summarised in
the Explanatory Memorandum.’
The Directors abstain, in the interests of corporate governance from making a recommendation in
relation to this resolution.
Resolution 16 – Amendment to Constitution
To consider and, if in favour, to pass the following resolution as a special resolution:
16
‘That, for the purposes of section 136(2) of the Corporations Act and for all other purposes, the
Company’s Constitution be amended in the manner set out in the Explanatory Memorandum, with
effect from the close of the Meeting.’
The Directors unanimously recommend that you vote in favour of this resolution.
Dated 25 October 2024
By order of the Board
Phillip Hains
Joint Company Secretary
Notice of Annual General Meeting
7
Voting Exclusion Statement
Corporations Act
Resolution 1 - The Company will disregard votes cast by a member of the Key Management Personnel
details of whose remuneration are included in the Remuneration Report, or a closely related party of such
a member, in contravention of section 250R or 250BD Corporations Act. Restrictions also apply to votes
cast as proxy unless exceptions apply.
For the purposes of section 224 Corporations Act, the Company will not disregard a vote if:
(a)
it is cast by a person as a proxy appointed in writing that specifies how the proxy is to vote on
the proposed resolution; and
(b)
it is not cast on behalf of a related party or associate of a related party of the Company to whom
the resolution would permit a financial benefit to be given or an associate of such a related party.
Listing Rules
In accordance with the Listing Rule 14.11, the Company will disregard votes cast in favour of the
resolution by or on behalf of:
Resolution 5 – Ratification of
prior issue of Tranche 1 Shares
the Sophisticated Investors or any person who participated in the
issue or is a counterparty to the agreement being approved or
any associate of those persons.
Resolution 6 – Approval to issue
Remuneration Options to
Director – Mr Paul Hopper
a person referred to in Listing Rule 10.14.1, 10.14.2 or 10.14.3
who is eligible to participate in the Company’s Omnibus Incentive
Plan, and these persons’ associates.
Resolution 7 – Approval to issue
Incentive Options to Director –
Mr Riccardo Canevari
a person referred to in Listing Rule 10.14.1, 10.14.2 or 10.14.3
who is eligible to participate in the Company’s Omnibus Incentive
Plan, and these persons’ associates.
Resolutions 8 and 9 – Approval
to issue Incentive Options and
Remuneration Options to
Director – Mr Ian Turner
a person referred to in Listing Rule 10.14.1, 10.14.2 or 10.14.3
who is eligible to participate in the Company’s Omnibus Incentive
Plan, and these persons’ associates.
Resolution 10 – Approval to
issue Remuneration Options to
Director – Mr Noel Donnelly
a person referred to in Listing Rule 10.14.1, 10.14.2 or 10.14.3
who is eligible to participate in the Company’s Omnibus Incentive
Plan, and these persons’ associates.
Resolution 11 – Approval to
issue Remuneration Options to
Director – Mr Phillip Hains
a person referred to in Listing Rule 10.14.1, 10.14.2 or 10.14.3
who is eligible to participate in the Company’s Omnibus Incentive
Plan, and these persons’ associates.
Resolution 12 – Approval to
issue Remuneration Options to
Director – Ms Hester Larkin
a person referred to in Listing Rule 10.14.1, 10.14.2 or 10.14.3
who is eligible to participate in the Company’s Omnibus Incentive
Plan, and these persons’ associates.
Resolution 13 – Approval to
issue Remuneration Options to
Director – Dr Leila Alland
a person referred to in Listing Rule 10.14.1, 10.14.2 or 10.14.3
who is eligible to participate in the Company’s Omnibus Incentive
Plan, and these persons’ associates.
Notice of Annual General Meeting
8
Resolution 14 – Approval of
10% capacity under Listing Rule
7.1A
a person, or any associate of that person, who is expected to
participate in, or will obtain a material benefit as a result of, the
proposed issue (except a benefit solely by reason of being a
holder of Shares).
NB. In accordance with Listing Rule 14.11 and the relevant note
under that rule concerning Rule 7.1A, as at the date of this Notice
of Meeting it is not known who may participate in the proposed
issue (if any). On that basis, no security holders are currently
excluded.
Resolution 15 – Approval to
issue Equity Securities under the
Omnibus Incentive Plan
any person who is eligible to participate in the Omnibus Incentive
Plan and each of their associates.
However, this does not apply to a vote cast in favour of a resolution by:
(a)
a person as proxy or attorney for a person who is entitled to vote on the resolution, in
accordance with directions given to the proxy or attorney to vote on the resolution in that way;
or
(b)
the chair of the meeting as proxy or attorney for a person who is entitled to vote on the
resolution, in accordance with a direction given to the chair to vote on the resolution as the chair
decides; or
(c)
a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a
beneficiary provided the following conditions are met:
(i)
the beneficiary provides written confirmation to the holder that the beneficiary is not
excluded from voting, and is not an associate of a person excluded from voting, on the
resolution; and
(ii)
the holder votes on the resolution in accordance with directions given by the beneficiary
to the holder to vote in that way.
Notice of Annual General Meeting
9
Notes
(a)
Terms used in this Notice of Meeting which are defined in the Explanatory Memorandum have the
meaning given to them in the Explanatory Memorandum.
(b)
Subject to the Corporations Act, including sections 250R and 250BD, a Shareholder who is
entitled to attend and cast a vote at the meeting is entitled to appoint a proxy.
(c)
The proxy need not be a Shareholder of the Company. A Shareholder who is entitled to cast two
or more votes may appoint two proxies and may specify the proportion or number of votes each
proxy is appointed to exercise.
(d)
If you wish to appoint a proxy and are entitled to do so, then complete and return the attached
proxy form to the Company’s share registry Automic Registry Service Limited as detailed in the
attached proxy form.
(e)
You can also lodge your proxy online at https://investor.automic.com.au/#/loginsah which is also
located on the front of the accompanying proxy form. Alternatively, you can scan the QR code
with your mobile device.
(f)
To be effective, the proxy must be received at the share registry of the Company no later than
10.00 am (Melbourne time) on Saturday, 23 November 2024 (48 hours before the
commencement of the meeting).
(g)
A corporation may elect to appoint a representative in accordance with the Corporations Act in
which case the Company will require written proof of the representative’s appointment which
must be lodged with or presented to the Company before the meeting.
(h)
The Company has determined under regulation 7.11.37 Corporations Regulations that for the
purpose of voting at the meeting or adjourned meeting, securities are taken to be held by those
persons recorded in the Company’s register of Shareholders as at 7:00 pm (Melbourne time) on
Saturday, 23 November 2024.
(i)
If you have any queries, including how to cast your votes, please contact the Company’s
registered office on 03 9824 5254 (within Australia) or +61 3 9824 5254 (outside Australia)
during business hours.
Notice of Annual General Meeting
10
Explanatory Memorandum
Radiopharm Theranostics Limited ACN 647 877 889 (Company)
This Explanatory Memorandum accompanies the notice of Annual General Meeting of the Company to be
held online by Zoom on Monday, 25 November 2024 at 10.00 am (Melbourne time).
The Explanatory Memorandum has been prepared to assist Shareholders in determining how to vote on
the resolutions set out in the Notice of Meeting and is intended to be read in conjunction with the Notice
of Meeting.
Financial Statements and Reports
1
The Corporations Act 2001 (Cth) (Corporations Act) requires that the report of the Directors,
the auditor’s report and the financial report be laid before the Annual General Meeting.
2
Apart from the matters involving remuneration which are required to be voted upon, neither the
Corporations Act nor the Constitution requires a vote of Shareholders at the Annual General
Meeting on the financial statements and reports.
3
Shareholders will be given a reasonable opportunity at the meeting to raise questions and make
comments on these reports.
4
In addition to asking questions at the meeting, Shareholders may address written questions to
the chairman about the management of the Company or to the Company’s auditor, Grant
Thornton Australia, if the question is relevant to:
(a)
the content of the auditor’s report; or
(b)
the conduct of its audit of the annual financial report to be considered at the meeting.
Note: Under section 250PA(1) Corporations Act, a Shareholder must submit the question to the Company no
later than the fifth business day before the day on which the Annual General Meeting is held.
5
Written questions for the auditor must be delivered by 5:00 pm on Monday, 18 November 2024.
Please send any written questions for Grant Thornton to:
The Company Secretary
PO Box 655
Carlton South, VIC 3053
or via email to: cfoservices@acclime.com
Resolution 1: Remuneration Report
6
The Remuneration Report is contained in the Annual Report. A copy is available on the
Company’s website.
7
The Corporations Act requires that the Remuneration Report be put to a vote of Shareholders.
8
The resolution of Shareholders is advisory only and not binding on the Company. The Board will
take the discussion at the meeting into consideration when determining the Company’s
Notice of Annual General Meeting
11
remuneration policy and appropriately respond to any concerns Shareholders may raise in
relation to remuneration issues.
9
10
The Remuneration Report:
(a)
reports and explains the remuneration arrangements in place for non-executive Directors,
executive Directors and senior management; and
(b)
explains Board policies in relation to the nature and value of remuneration paid to nonexecutive Directors, executives and senior managers within the Company.
The Chairman will give Shareholders a reasonable opportunity to ask questions about, or to make
comments on, the Remuneration Report.
Directors’ Recommendation
11
As the resolution relates to matters including the remuneration of the Directors, the Board, as a
matter of corporate governance and in accordance with the spirit of section 250R(4) Corporations
Act, makes no recommendation regarding this resolution.
Resolution 2: Re-election of Director – Mr Ian Turner
12
Mr Turner was appointed as a Director of the Company on 1 April 2021 and retires in accordance
with rule 19.3 of the Company’s Constitution and Listing Rule 14.4 and stands for election.
13
Mr Turner is a highly experienced radiopharmaceutical and nuclear medicine supply and
manufacturing expert with a distinguished C-level career across some of the leading corporations
in the sector including CEO and President of Siemens PETNET Solutions from 2010-2012. Prior to
that role, he was General Manager of ANSTO Radiopharmaceuticals in Sydney Australia,
Australia's leading manufacturer of radioisotopes for the nuclear medicine sector. He was also
Executive Director of PETNET Australia Pty Ltd. He spent a decade in various C-level roles at
Varian Inc in Palo Alto and Melbourne. Mr Turner was also previously a Director of Coqui
Pharmaceuticals until 2019, a company involved in the supply of radioisotopes in the US.
Directors’ Recommendation
14
The Directors (with Mr Turner abstaining) unanimously recommend the re-election of Mr Turner
to the Board.
Resolution 3: Election of Director – Mr Phillip Hains
15
Mr Hains was previously appointed to fill a casual vacancy as a Director of the Company on 26
March 2024 and retires in accordance with rule 19.3 of the Company’s Constitution and Listing
Rule 14.4 and stands for election.
16
Mr Hains is Partner of Acclime and Managing Director of Listed CFO Services. Mr Hains founded
The CFO Solution, a leading firm acquired by Acclime in August 2023. With extensive experience,
Mr Hains specialises in tailored back-office solutions for listed and pre-listed companies
(particularly biotechnology companies). His expertise spans strategic finance support, from
accounts payable to C-suite guidance, across various growth stages. Mr Hains holds a Master of
Business Administration from RMIT and a Public Practicing Certificate from the Institute of
Chartered Accountants.
Notice of Annual General Meeting
12
Directors’ Recommendation
17
The Directors (with Mr Hains abstaining) unanimously recommend the appointment of Mr Hains
to the Board.
Resolution 4: Election of Director – Mr Noel Donnelly
18
Mr Donnelly was previously appointed to fill a casual vacancy as a Director of the Company on 2
October 2024 and retires in accordance with rule 19.3 of the Company’s Constitution and Listing
Rule 14.4 and stands for election.
19
Mr Donnelly brings over 25 years of leadership experience in finance, strategy, and operations
within the biopharmaceutical and biotechnology industries. He has a distinguished track record
of building and leading cross-functional teams, driving corporate governance, and executing
complex financial strategies that support rapid company growth. Currently serving as Chief
Financial Officer at PepGen Inc., Mr Donnelly oversaw the company's financial strategy as it
undertook a successful Initial Public Offering in 2022, raising US$120M, and leading subsequent
financing efforts that secured an additional US$90M. His leadership was pivotal as PepGen
advanced two clinical assets into Phase 1 and 2 trials.
20
Before joining PepGen, Mr Donnelly was CFO at EIP Pharma (now CervoMed), where he led the
company's IPO planning phase. His career also includes a 15-year tenure at Takeda/Shire PLC,
where he held various senior roles, including Vice President of R&D Business Operations. At
Shire, Mr Donnelly led critical R&D integrations, overseeing more than US$160 billion in
integration planning and execution, and was instrumental in shaping the company’s portfolio
management strategy, helping prioritise key development assets.
21
In addition to his operational expertise, Mr Donnelly is highly experienced in business partnering,
valuation, investor relations, and decision support analysis, making him a trusted advisor to both
executive leadership teams and boards of directors. Mr Donnelly holds an MBA from the F. W.
Olin Graduate School of Business at Babson College and a Bachelor of Science in Nuclear
Engineering from the University of Massachusetts, Lowell.
Directors’ Recommendation
22
The Directors (with Mr Donnelly abstaining) unanimously recommend the appointment of Mr
Hains to the Board.
Resolution 5: Ratification of prior issue of Tranche 1 Shares
Background
23
24
As announced to the ASX on 25 June 2024, the Company undertook a $70 million (in aggregate)
capital raise by way of a:
(a)
strategic equity investment by Lantheus Holdings, Inc. of $7.5 million at $0.05 per Share,
which represented a 47% premium to last closing price of $0.034 on 19 June 2024; and
(b)
two-tranche placement of approximately 1,563 million new fully paid ordinary shares
(Placement Shares) issued to institutional and sophisticated investors (Sophisticated
Investors) to raise an additional $62.5 million at $0.04 per Share, representing an 18%
premium to last closing price of $0.034 on 19 June 2024 (Placement).
The Placement was split as follows:
Notice of Annual General Meeting
13
25
(a)
approximately 597 million Placement Shares were issued on 1 July 2024 under the
Company’s existing placement capacity under Listing Rules 7.1 and 7.1A (Tranche 1
Shares); and
(b)
the remaining 966 million Placement Shares were issued on 21 August 2024 following
approval by Shareholders at the Company’s extraordinary general meeting held on 14
August 2024 (EGM).
At an earlier extraordinary general meeting held on 15 April 2024, Shareholders ratified the
issuance of 500 million placement shares, which were issued as Tranche 1 Shares. The purpose
of Resolution 5 is for Shar
Share your feedback
Discover